The ADCY7 antibody is a crucial tool for investigating the function and expression of adenylate cyclase 7 (ADCY7), a membrane-associated enzyme encoded by the ADCY7 gene. Belonging to the adenylate cyclase family, ADCY7 catalyzes the conversion of ATP to cyclic AMP (cAMP), a secondary messenger regulating diverse cellular processes, including metabolism, gene expression, and immune responses. ADCY7 is uniquely regulated by G-protein-coupled receptors (GPCRs) and plays roles in immune cell signaling, neuronal function, and cancer progression. Its dysregulation has been linked to inflammatory diseases, neurological disorders, and tumorigenesis, making it a target for therapeutic research.
The ADCY7 antibody is designed to detect endogenous ADCY7 protein in various experimental applications, such as Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. It typically targets specific epitopes within the ADCY7 protein, often validated using knockout controls or siRNA knockdown to ensure specificity. Host species (e.g., rabbit, mouse) and clonality (monoclonal/polyoclonal) vary by commercial source. Researchers rely on this antibody to study ADCY7's tissue distribution, subcellular localization, and expression changes under pathological conditions. Recent studies highlight its utility in exploring ADCY7's role in cancer metastasis, immune cell activation, and cAMP-mediated signaling pathways. Proper validation and optimization of the antibody are critical to avoid cross-reactivity with other adenylate cyclase isoforms (e.g., ADCY1-6. 8-10), ensuring accurate experimental outcomes.